LifeAssay Diagnostics won two Grand Challenges Grants from the Bill and Melinda Gates Foundation to develop and commercialize a low-cost PrCr urine dipstick to combat the devastating effects of Preeclampsia in developing countries.
The World Health Organization
estimates that Preeclampsia/Eclampsia accounts for at least 16% of maternal deaths. Early identification of women at high risk for developing PE/E is key to linking them to proper health interventions to avoid complications and death.
The PrCr urine dipstick that has shown strong laboratory-based performance and high usability within ANC settings.